Last reviewed · How we verify

NCT05689528

The Screening of Neuroprotective Biomarkers After Acute Ischemic Stroke

Completed Last updated 19 January 2023
What this trial tests

trial in Acute Ischemic Stroke in 453 participants. Completed in 31 July 2021.

Timeline
1 July 2017
Primary endpoint
30 June 2021
31 July 2021

Quick facts

Lead sponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment453
Start date1 July 2017
Primary completion30 June 2021
Estimated completion31 July 2021
Sites1 location across China

Conditions studied

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Adults 50 to 85, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neuroprotection is expected to be an important therapeutic strategy for acute ischemic stroke(AIS), but almost all neuroprotective drugs proved effective in rodent models have failed after entering clinical trials. This study aims to screen the differentially expressed proteins in peripheral blood of patients with acute ischemic stroke and with further study in the animal model of non-human primate cerebral infarction, we may determine the biomarkers that can evaluate the efficacy of neuroprotective drugs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05689528.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing